Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

mirvetuximab soravtansine 1liposomal doxorubicin 1Paclitaxel 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma × mirvetuximab soravtansine × 90 days × Clear all
NCT04274426 2026-05-13

MIROVA

AGO Research GmbH

Phase 2 Active not recruiting
136 enrolled
Gynecologic

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡